Zydus completes enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH
- by Team ABLE - 18 Jun, 2019
Zydus Cadilahas announced that the company has completed enrolment of 104 patients with Non-Alcoholic Fatty Liver Disease (NAFLD), including Non-Alcoholic SteatoHepatitis (NASH) across 20 clinical sites inthe United States of America.
The trial will evaluate the percentage change from baseline in serum ALT levels in patients treated with Saroglitazar Magnesium as compared to placebo as the primary endpoint. The change in liver fat content as measured by magnetic resonance imaging will also be compared, along with several other secondary endpoints. This study is one of several EVIDENCES trials conducted to assess the effect of Saroglitazar Magnesium in various populations with NAFLD, including patients with NASH.
Speaking on the development, Pankaj R. Patel, Chairman, Zydus group said, "This is a major milestone in our innovation journey and we hope to report the top line results of this trial by the end of the year. In keeping with our mission of creating healthier, happier communities, we are committed towards developing this drug for millions of patients suffering from NASH, an unmet healthcare need.”
NASH is a significant unmet medical need, with an estimated 6.5 million adults in the United States and five major European countries having advanced NASH. NASH is a progressive disease of the liver. Starting with fat accumulation in liver, this condition can progress to cirrhosis and liver failure. NASH ranks as one of the major causes of cirrhosis in America, behind hepatitis C and alcoholic liver disease. Liver transplantation is the only option for managing advanced cirrhosis with liver failure. There are currently no treatments approved by the U.S. Food and Drug Administration (USFDA) for the treatment of NASH.
Saroglitazar Magnesium is an investigational molecule in USA, undergoing clinical evaluation for the treatment of liver diseases like Nonalcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC). Nonclinical studies have demonstrated that Saroglitazar Mg, because of its unique mechanism of engaging PPAR alpha and PPAR gamma, favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis.
The trial will evaluate the percentage change from baseline in serum ALT levels in patients treated with Saroglitazar Magnesium as compared to placebo as the primary endpoint.